drugset
drugset / Trial / NCT02215031

Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses of BI 44370 BS Solution in Healthy Male Volunteers

NCT02215031 ↗

Phase 1 Completed 23 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

Study to investigate safety, tolerability, and pharmacokinetics of BI 44370 BS solution for intravenous (i.v.) infusion

Timeline

Start
2008-09
Primary completion
2008-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 44370 Small molecule — Intravenous

Indications

No indication recorded.